MX2023010831A - Composiciones y metodos para tratar enfermedades neurologicas. - Google Patents
Composiciones y metodos para tratar enfermedades neurologicas.Info
- Publication number
- MX2023010831A MX2023010831A MX2023010831A MX2023010831A MX2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- neurologic diseases
- treating neurologic
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163546P | 2021-03-19 | 2021-03-19 | |
| PCT/US2022/020687 WO2022197885A1 (en) | 2021-03-19 | 2022-03-17 | Compositions and methods for treating neurologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010831A true MX2023010831A (es) | 2023-09-27 |
Family
ID=83320987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010831A MX2023010831A (es) | 2021-03-19 | 2022-03-17 | Composiciones y metodos para tratar enfermedades neurologicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240165077A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230159546A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117355525A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022239497A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3212092A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL306063A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010831A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022197885A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026064542A1 (en) * | 2024-09-18 | 2026-03-26 | Cognition Therapeutics, Inc. | 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms |
| WO2026119142A1 (zh) * | 2024-12-03 | 2026-06-11 | 浙江径科医药有限公司 | 一种氘代异吲哚啉化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| WO2015116923A1 (en) * | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| ES3063712T3 (en) * | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| US20200338045A1 (en) * | 2017-11-01 | 2020-10-29 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| JP2022537581A (ja) * | 2019-06-21 | 2022-08-26 | クラリス コーポレーション | Ppm1阻害剤およびその使用方法 |
| CN110283082A (zh) * | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
-
2022
- 2022-03-17 CA CA3212092A patent/CA3212092A1/en active Pending
- 2022-03-17 US US18/280,565 patent/US20240165077A1/en not_active Abandoned
- 2022-03-17 MX MX2023010831A patent/MX2023010831A/es unknown
- 2022-03-17 EP EP22772183.4A patent/EP4308565A4/en active Pending
- 2022-03-17 JP JP2023556900A patent/JP2024510249A/ja active Pending
- 2022-03-17 CN CN202280035073.7A patent/CN117355525A/zh active Pending
- 2022-03-17 WO PCT/US2022/020687 patent/WO2022197885A1/en not_active Ceased
- 2022-03-17 KR KR1020237035979A patent/KR20230159546A/ko active Pending
- 2022-03-17 AU AU2022239497A patent/AU2022239497A1/en active Pending
- 2022-03-17 IL IL306063A patent/IL306063A/en unknown
-
2026
- 2026-02-04 US US19/529,760 patent/US20260166006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117355525A (zh) | 2024-01-05 |
| AU2022239497A1 (en) | 2023-09-21 |
| EP4308565A4 (en) | 2025-01-01 |
| WO2022197885A1 (en) | 2022-09-22 |
| KR20230159546A (ko) | 2023-11-21 |
| US20240165077A1 (en) | 2024-05-23 |
| US20260166006A1 (en) | 2026-06-18 |
| IL306063A (en) | 2023-11-01 |
| CA3212092A1 (en) | 2022-09-22 |
| EP4308565A1 (en) | 2024-01-24 |
| JP2024510249A (ja) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| MY208749A (en) | Biligand drug conjugates and uses thereof | |
| EP4548918A3 (en) | Tricyclic compounds as inhibitors of kras | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| TW200806299A (en) | Treatment of pain | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| MA55027B1 (fr) | Formulations plaisante au goût | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| WO2020257631A3 (en) | Ppm1a inhibitors and methods of using same | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| WO2022246251A3 (en) | Compounds for modulating unc13a expression | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| TW200639159A (en) | Treatment of pain | |
| WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| KR102467285B9 (ko) | 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물 | |
| WO2024141660A3 (en) | Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases | |
| WO2023107630A3 (en) | Amino alcohol compounds and uses thereof |